

.

Printed as of 4/25/2024

Disclosures

. .

| Personal Commercial (15) | | | |
|-----------------------------|---------------------------|--------------------------|-------------------------------|
| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
| Self | | | |
| Amarin | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Amarin | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Astra-Zeneca | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Сеарго | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| DalCor Pharmaceuticals | Stock | Significant (>= \$5,000) | Stable Ischemic Heart Disease |
| DalCor Pharmaceuticals | Research/Research Grants | Significant (>= \$5,000) | Stable Ischemic Heart Disease |
| DalCor Pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) | Stable Ischemic Heart Disease |
| Esperion | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| HLS Therapeutics | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| lonis | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Merck & Co., Inc. | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Novartis Corporation | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Pfizer | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| Pharmascience | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| | | | |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | *‡* Trial Name

Agreement

Certified Education Attestation | Signed on 10/9/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/9/2023 URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

On-Going Obligation Agreement | Signed on 10/9/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.